Deletion of CXCR4 in cardiomyocytes exacerbates cardiac dysfunction following isoproterenol administration

Gene Therapy

Volumn 21, Issue 5, 2014, Pages 496-506

  Wang, E R ^a   Jarrah, A A ^a   Benard, L ^a   Chen, J ^a   Schwarzkopf, M ^a   Hadri, L ^a   Tarzami, S T ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; CHEMOKINE RECEPTOR CXCR4; ISOPRENALINE; PARVOVIRUS VECTOR; STROMAL CELL DERIVED FACTOR 1ALPHA; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CARDIOTONIC AGENT; CXCR4 PROTEIN, MOUSE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; STROMAL CELL DERIVED FACTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; GENE DELETION; HEART CONTRACTION; HEART EJECTION FRACTION; HEART FAILURE; HEART FRACTIONAL SHORTENING; HEART HYPERTROPHY; HEART MITOCHONDRION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART PROTECTION; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; VIRAL GENE DELIVERY SYSTEM; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CARDIOMEGALY; CHEMICALLY INDUCED; CYTOLOGY; DEPENDOPARVOVIRUS; DRUG EFFECTS; FIBROSIS; GENE INACTIVATION; GENE TRANSFER; GENE VECTOR; GENETICS; HEART STROKE VOLUME; METABOLISM; MITOCHONDRION; PATHOLOGY;

ADRENERGIC BETA-AGONISTS; ANIMALS; APOPTOSIS; CARDIOMEGALY; CARDIOTONIC AGENTS; CHEMOKINE CXCL12; DEPENDOVIRUS; FIBROSIS; GENE KNOCKOUT TECHNIQUES; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GLYCOGEN SYNTHASE KINASE 3; HEART FAILURE; ISOPROTERENOL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MITOCHONDRIA; MYOCYTES, CARDIAC; RECEPTORS, ADRENERGIC, BETA; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION; STROKE VOLUME;

EID: 84900001445     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2014.23     Document Type: Article

References (51)

1. Tissier R, Berdeaux A, Ghaleh B, Couvreur N, Krieg T, Cohen MV et al. Making the heart resistant to infarction: how can we further decrease infarct size? Front Biosci 2008; 13: 284-301
2. Yellon DM, Baxter GF. Protecting the ischaemic and reperfused myocardium in acute myocardial infarction: distant dream or near reality? Heart 2000; 83: 381-387
3. Carden DL, Granger DN. Pathophysiology of ischaemia-reperfusion injury. J Pathol 2000; 190: 255-266
4. Katholi RE, Couri DM. Left ventricular hypertrophy: major risk factor in patients with hypertension: update and practical clinical applications. Int J Hypertens 2011; 2011: 495349
5. El-Armouche A, Zolk O, Rau T, Eschenhagen T. Inhibitory G-proteins and their role in desensitization of the adenylyl cyclase pathway in heart failure. Cardiovasc Res 2003; 60: 478-487
6. Zierhut W, Zimmer HG. Significance of myocardial alpha- and beta-adrenoceptors in catecholamine-induced cardiac hypertrophy. Circ Res 1989; 65: 1417-1425
7. Ungerer M, Bohm M, Elce JS, Erdmann E, Lohse MJ. Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. Circulation 1993; 87: 454-463
8. Hadcock JR, Ros M, Watkins DC, Malbon CC. Cross-regulation between G-proteinmediated pathways. Stimulation of adenylyl cyclase increases expression of the inhibitory G-protein, Gi alpha 2. J Biol Chem 1990; 265: 14784-14790
9. Zhao M, Fajardo G, Urashima T, Spin JM, Poorfarahani S, Rajagopalan V et al. Cardiac pressure overload hypertrophy is differentially regulated by beta-adrenergic receptor subtypes. Am J Physiol Heart Circ Physiol 2010; 301: H1461-H1470
10. Port JD, Bristow MR. Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure. J M Cell Cardiol 2001; 33: 887-905
11. Moore MA, Hattori K, Heissig B, Shieh JH, Dias S, Crystal RG et al. Mobilization of endothelial and hematopoietic stem and progenitor cells by adenovectormediated elevation of serum levels of SDF-1, VEGF, and angiopoietin-1. Ann N Y Acad Sci 2001; 938: 36-45; discussion 45-37
12. Hiasa K, Ishibashi M, Ohtani K, Inoue S, Zhao Q, Kitamoto S et al. Gene transfer of stromal cell-derived factor-1alpha enhances ischemic vasculogenesis and angiogenesis via vascular endothelial growth factor/endothelial nitric oxide synthase-related pathway: next-generation chemokine therapy for therapeutic neovascularization. Circulation 2004; 109: 2454-2461
13. Onuffer JJ, Horuk R. Chemokines, chemokine receptors and small-Molecule antagonists: recent developments. Trends Pharmacol Sci 2002; 23: 459-467
14. Chen C, Li J, Bot G, Szabo I, Rogers TJ, Liu-Chen LY. Heterodimerization and cross-desensitization between the mu-opioid receptor and the chemokine CCR5 receptor. Eur J Pharmacol 2004; 483: 175-186
15. Insel PA, Tang CM, Hahntow I, Michel MC. Impact of GPCRs in clinical medicine: monogenic diseases, genetic variants and drug targets. Biochim Biophys Acta 2007; 1768: 994-1005
16. Busillo JM, Benovic JL. Regulation of CXCR4 signaling. Biochim Biophys Acta 2007; 1768: 952-963
17. LaRocca TJ, Schwarzkopf M, Altman P, Zhang S, Gupta A, Gomes I et al. beta2-Adrenergic receptor signaling in the cardiac myocyte is modulated by interactions with CXCR4. J Cardiovasc Pharmacol 2010; 56: 548-559
18. Lou Q, Janardhan A, Efimov IR. Remodeling of calcium handling in human heart failure. Adv Exp Med Biol 2012; 740: 1145-1174
19. Larocca TJ, Jeong D, Kohlbrenner E, Lee A, Chen J, Hajjar RJ et al. CXCR4 gene transfer prevents pressure overload induced heart failure. J Mol Cell Cardiol 2012; 53: 223-232
20. Takefuji M, Wirth A, Lukasova M, Takefuji S, Boettger T, Braun T et al. G13-Mediated signaling pathway is required for pressure overload-induced cardiac remodeling and heart failure. Circulation 2012; 126: 1972-1982
21. Pan J, Fukuda K, Kodama H, Sano M, Takahashi T, Makino S et al. Involvement of gp130-Mediated signaling in pressure overload-induced activation of the JAK/ STAT pathway in rodent heart. Heart Vessels 1998; 13: 199-208
22. Haq S, Choukroun G, Kang ZB, Ranu H, Matsui T, Rosenzweig A et al. Glycogen synthase kinase-3beta is a negative regulator of cardiomyocyte hypertrophy. J Cell Biol 2000; 151: 117-130
23. Anderson ME. CaMKII and a failing strategy for growth in heart. J Clin Invest 2009; 119: 1082-1085
24. Serneri GG, Modesti PA, Boddi M, Cecioni I, Paniccia R, Coppo M et al. Cardiac growth factors in human hypertrophy. Relations with myocardial contractility and wall stress. Circ Res 1999; 85: 57-67
25. Baker KM, Chernin MI, Wixson SK, Aceto JF. Renin-angiotensin system involvement in pressure-overload cardiac hypertrophy in rats. Am J Physiol 1990; 259: H324-H332
26. Jaski BE, Jessup ML, Mancini DM, Cappola TP, Pauly DF, Greenberg B et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail 2009; 15: 171-181
27. Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998; 393: 595-599
28. Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y et al. Defects of B-cell lymphopoiesis and bone-Marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996; 382: 635-638
29. Ma Q, Jones D, Borghesani PR, Segal RA, Nagasawa T, Kishimoto T et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc Natl Acad Sci USA 1998; 95: 9448-9453
30. Agarwal U, Ghalayini W, Dong F, Weber K, Zou YR, Rabbany SY et al. Role of cardiac myocyte CXCR4 expression in development and left ventricular remodeling after acute myocardial infarction. Circ Res 2010; 107: 667-676
31. Berenji K, Drazner MH, Rothermel BA, Hill JA. Does load-induced ventricular hypertrophy progress to systolic heart failure? Am J Physiol Heart Circ Physiol 2005; 289: H8-H16
32. Schiaffino S, Samuel JL, Sassoon D, Lompre AM, Garner I, Marotte F et al. Nonsynchronous accumulation of alpha-skeletal actin and beta-Myosin heavy chain mRNAs during early stages of pressure-overload-induced cardiac hypertrophy demonstrated by in situ hybridization. Circ Res 1989; 64: 937-948
33. Balabanian K, Lagane B, Infantino S, Chow KY, Harriague J, Moepps B et al. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem 2005; 280: 35760-35766
34. Rajagopal S, Kim J, Ahn S, Craig S, Lam CM, Gerard NP et al. Beta-arrestin- but not G protein-Mediated signaling by the "decoy" receptor CXCR7. Proc Natl Acad Sci USA 2010; 107: 628-632
35. Eom TY, Roth KA, Jope RS. Neural precursor cells are protected from apoptosis induced by trophic factor withdrawal or genotoxic stress by inhibitors of glycogen synthase kinase 3. J Biol Chem 2007; 282: 22856-22864
36. Rimbaud S, Garnier A, Ventura-Clapier R. Mitochondrial biogenesis in cardiac pathophysiology. Pharmacol Rep 2009; 61: 131-138
37. Moreno-Lastres D, Fontanesi F, Garcia-Consuegra I, Martin MA, Arenas J, Barrientos A et al. Mitochondrial complex I plays an essential role in human respirasome assembly. Cell Metab 2012; 15: 324-335
38. Kaya Y, Cebi A, Soylemez N, Demir H, Alp HH, Bakan E. Correlations between oxidative DNA damage, oxidative stress and coenzyme Q10 in patients with coronary artery disease. Int J Med Sci 2012; 9: 621-626
39. Dong F, Harvey J, Finan A, Weber K, Agarwal U, Penn MS. Myocardial CXCR4 expression is required for mesenchymal stem cell mediated repair following acute myocardial infarction. Circulation 2012; 126: 314-324
40. Entman ML, Smith CW. Postreperfusion inflammation: a model for reaction to injury in cardiovascular disease. Cardiovasc Res 1994; 28: 1301-1311
41. Hunter JJ, Chien KR. Signaling pathways for cardiac hypertrophy and failure. N Engl J Med 1999; 341: 1276-1283
42. Gaasch WH. Left ventricular radius to wall thickness ratio. Am J Cardiol 1979; 43: 1189-1194
43. Hudlicka O, Brown M, Egginton S. Angiogenesis in skeletal and cardiac muscle. Physiol Rev 1992; 72: 369-417
44. Hoeks J, van Baak MA, Hesselink MK, Hul GB, Vidal H, Saris WH et al. Effect of beta1- and beta2-adrenergic stimulation on energy expenditure, substrate oxidation, and UCP3 expression in humans. Am J Physiol Endocrinol Metab 2003; 285: E775-E782
45. Beurel E, Jope RS. The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol 2006; 79: 173-189
46. Gomez-Sintes R, Hernandez F, Lucas JJ, Avila J. GSK-3 mouse models to study neuronal apoptosis and neurodegeneration. Front Mol Neurosci 2011; 4: 45
47. Subramaniam A, Jones WK, Gulick J, Wert S, Neumann J, Robbins J et al. Tissue-specific regulation of the alpha-Myosin heavy chain gene promoter in transgenic mice. J Biol Chem 1991; 266: 24613-24620
48. Petrich BG, Molkentin JD, Wang Y. Temporal activation of c-Jun N-terminal kinase in adult transgenic heart via cre-loxP-Mediated DNA recombination. FASEB J 2003; 17: 749-751
49. Nie Y, Waite J, Brewer F, Sunshine MJ, Littman DR, Zou YR. The role of CXCR4 in maintaining peripheral B cell compartments and humoral immunity. J Exp Med 2004; 200: 1145-1156
50. Agah R, Frenkel PA, French BA, Michael LH, Overbeek PA, Schneider MD. Gene recombination in postmitotic cells. Targeted expression of Cre recombinase provokes cardiac-restricted, site-specific rearrangement in adult ventricular muscle in vivo. J Clin Invest 1997; 100: 169-179
51. Tarzami ST, Calderon TM, Deguzman A, Lopez L, Kitsis RN, Berman JW. MCP-1/ CCL2 protects cardiac myocytes from hypoxia-induced apoptosis by a G(alphai)- independent pathway. Biochem Biophys Res Commun 2005; 335: 1008-1016.